INTRODUCTION
============

The Zuni Indians are experiencing interrelated epidemics of chronic kidney disease (CKD) and related features of the cardiometabolic syndrome including obesity, diabetes, dyslipidemia, and hypertension that are intermediate phenotypes for CKD ([@B62]; [@B57]; [@B54]; [@B46]). Ethnicity also influences the risk for the development of CKD and related phenotypes ([@B36]). Genetic studies, including candidate gene and genome-wide association studies (GWAS), have been conducted to elucidate the effects of specific genes on the variation in CKD and cardiometabolic risk factors. These include studies conducted in Caucasians ([@B33]; [@B51]), African Americans ([@B17]; [@B76]; [@B5]), Asians ([@B79]; [@B76]), Mexican Americans ([@B20]; [@B67]), Pima Indians ([@B4]; [@B30], [@B31]), and in the 13 American Indian tribes participating in the Strong Heart Family Study ([@B24]; [@B70]). To decrease the burden of kidney disease and related intermediate phenotypes in the Zuni Pueblo, we established the Zuni Kidney Project (ZKP) in partnership with the Indian Health Service, University of New Mexico Health Sciences Center, Texas Biomedical Research Institute and Dialysis Clinic, Inc. (DCI; [@B62]).

The Zuni Indians reside in the Zuni Pueblo, located in McKinley County, NM, USA. The population was 6,302 in the 2010 US Census and 97% of inhabitants were American Indians (Zuni Pueblo Quick Facts). Emigration and immigration rates are low and therefore the population is relatively endogamous. The majority of adults work as artisans, making jewelry and fetishes. The ZKP previously conducted a population-based, cross-sectional survey that reported high prevalence estimates, age-and sex-adjusted to the Zuni population, for decreased estimated glomerular filtration rate (eGFR; [@B54]), albuminuria ([@B57]), and hematuria ([@B66]). Prevalence estimates for albuminuria and hematuria were higher for diabetic than non-diabetic participants ([@B57]). The prevalence of end-stage renal disease (ESRD) among the Zuni Indians, adjusted for age and gender, was 20.0-, 4.4-, and 5.6-fold higher than that among European-- and African--Americans and the composite estimate for all American Indians ([@B57]).

Recently the ZKP conducted the Genetics of Kidney Disease in Zuni Indians (GKDZI) Study to explore the hypothesis that genetic factors modulate susceptibility to CKD and related phenotypes. Studies of extended families, such as GKDZI, offer advantages over studies of sib pairs or unrelated individuals for gene discovery since they have enhanced statistical power, are more homogenous and allow for greater genotyping quality control ([@B41]). The current manuscript presents the results of a GWAS in extended, multigenerational families of Zuni Indians.

MATERIALS AND METHODS {#s1}
=====================

STUDY DESIGN
------------

We conducted a GWAS in extended families of Zuni Indians. The study cohort consisted of 30 extended families, of which 28 were multigenerational. The families were ascertained through probands with kidney disease, who had at least one sibling with kidney disease. The Institutional Review Boards of all participating institutions and the Zuni Tribal Council approved the protocol. All participants gave written informed consent.

SETTING
-------

The study was conducted in the Zuni Pueblo. Recruitment occurred from February 2005 through May 2009. Data were collected from February 2005 through June 2009.

PARTICIPANTS
------------

We conducted a cross-sectional study of extended families ascertained through probands with CKD who had at least one sibling with CKD. Potential probands were identified from the ZKP's previous population-based study of kidney disease, which estimated the prevalence of incipient \[15%, (13.1--16.9%)\] and overt \[4.7% (3.6--5.8%)\] albuminuria among 1483 participants ([@B57]). Eligibility criteria for probands and affected siblings included age ≥18 years, a urine albumin to creatinine ratio (UACR) ≥0.2 in at least two of three urine samples or a reduced serum creatinine-based eGFR, modified for American Indians ([@B58]) using the Chronic Renal Insufficiency Cohort (CRIC) criteria ([@B23]). We invited all first-degree (parents, siblings, and offspring), second-degree (aunts, uncles, nieces, nephews, grandparents, and grandchildren) and third-degree (first cousins, great aunts, great uncles, etc.) relatives of probands and their spouses over 18 years of age to participate. See the consort diagram for details of the recruitment process (**Figure [1](#F1){ref-type="fig"}**). We used PEDSYS for data entry, quality control, report generation, and preparation of data files for statistical genetic analysis ([@B16]).

![**Study participants, flow diagram**.](fgene-06-00006-g001){#F1}

PHENOTYPIC VARIABLES
--------------------

A random blood sample was drawn from each participant. Blood was drawn for chemistry profile, hemoglobin A~1c~ (HbA~1c~), and serum creatinine and serum uric acid (SUA). We also measured serum triglycerides, HDL-, LDL-, and total serum cholesterol. We considered a participant to have diabetes if they met ≥1 of the following conditions: (1) history of diabetes, (2) random plasma glucose level ≥200 mg/dL ([@B3]), (3) HbA~1c~ ≥6.5% ([@B3]), (4) receiving diabetes medication(s). Three urine samples were collected on separate days from each participant. A participant was considered to have CKD if UACR ≥0.2 in ≥2 of 3 urine samples or if the eGFR was reduced. We also measured blood pressure and calculated body mass index (BMI). Participants were classified as hypertensive if they met ≥1 of the following conditions: (1) history of hypertension; (2) SBP or DBP ≥140 and ≥90 mm Hg, respectively (73--75), or (3) receiving antihypertensive medication(s).

GENOTYPIC VARIABLES
-------------------

DNA samples were obtained from peripheral blood mononuclear cells. We conducted genome-wide genotyping for 998 participants using the Illumina Human1M-Duo V3.0 BeadChips (Illumina, San Diego, CA, USA) that contain \~1.1 million single nucleotide polymorphism (SNP) assays. Illumina included sample-dependent and independent controls on their chips to test for accuracy of the procedure. Genotype calls were obtained after scanning on the Illumina BeadStation 500GX and analysis using the GenomeStudio software.

GENOTYPING QUALITY CONTROL
--------------------------

Specific SNPs were removed from analysis if they had call rates \<95% (4,867 SNPs), deviated from Hardy--Weinberg equilibrium (15), were mono-allelic (136,917) or had rare alleles occurring in fewer than five individuals (85,397). SNP genotypes were checked for Mendelian consistency using the program SimWalk ([@B60]). The estimates of allele frequencies and their SE were obtained by a maximum likelihood estimation method that accounts for pedigree structure using the Sequential Oligogenic Linkage Analysis Routines (SOLAR; <http://solar.txbiomedgenetics.org>), version 4.3 ([@B2]), a program package that is used for association analysis, linkage analysis, transmission disequilibrium tests, and other statistical genetic analyses. Linkage disequilibrium, taking relatedness into account, was also calculated using SOLAR. Missing genotypes were imputed from pedigree data using MERLIN version 1.1.2 ([@B1]).

REDUCING BIAS IN BIOLOGICAL SAMPLES
-----------------------------------

### Reducing bias in UACR

To minimize classification bias, we obtained three urine samples from each participant. The median interval between urine collections was 2 days. We classified albuminuria and hematuria using the mode of three urine samples. UACR was classified as normal (\<0.03), incipient (0.03--0.19), or overt (≥0.20). If all three samples were discordant, we used the median value. Urine albumin was measured using nephelometry ([@B45]; [@B49]).

### Reducing bias in eGFR

We used the four-variable Modification of Diet in Renal Disease (MDRD) Study equation, modified for use in American Indians to estimate GFR based on a single serum sample ([@B57]; [@B54]). Limitations of this equation include limited validation data in American Indians and the lack of calibration of the serum creatinine assay. Serum creatinine levels are influenced by muscle mass. We recognize that the CKD-EPI equation may out-perform the MDRD equation among people with near normal kidney function ([@B42]). Unfortunately, however, there are few data on the performance of the CKD-EPI equation among American Indians. We categorized eGFR using the [@B48] Kidney Disease Outcomes Quality Initiative (KDOQI; K/DOQI guidelines) and the CRIC age-specific criteria ([@B23]). Hyperuricemia was defined as SUA \>6 mg/dl in women and SUA \>7 mg/dl in men.

### Genome-wide association analysis (GWA analysis)

Measured genotype analyses were performed using SOLAR version 4.3 ([@B2]). The number of SNPs included in the GWA analysis was 884,161. All phenotypes were transformed by inverse normalization to meet assumptions of normality. We obtained residuals using linear regression models adjusted for age, sex, their interactions and higher order terms. Our subjects were ascertained for CKD. To adjust for ascertainment bias, we took a conservative approach by computing likelihood for pedigrees incorporating the CKD phenotype as an additional covariate for kidney function phenotypes (eGFR, UACR, and serum creatinine; [@B21]). Additional covariates included hypertension and diabetic status. Individuals excluded from analysis included those taking diabetes medications for analysis of HbA1c, antihypertensive medications for analysis of SBP and DBP, and statins for analysis of lipid traits (triglycerides, total-, HDL-, and LDL-cholesterol).

Each SNP genotype was converted in MERLIN version 1.1.2 ([@B1]) to a covariate measure equal to 0, 1, or 2 copies of the minor allele (or, for missing genotypes, the weighted covariate based on imputation). These covariates were included in the variance-components mixed models for measured genotype analyses ([@B6]) versus null models that incorporated the random effect of kinship and fixed effects such as age, sex, their interaction and higher order terms. For the initial GWA screen, we tested each SNP covariate independently as a one degree of freedom likelihood ratio test. An adjusted alpha value for significance, using a Moskvina--Schmidt calculation ([@B47]) based on the effective number of independent SNPs given LD (*n* = 323,965 SNPs) in the Zuni families, provided the adjusted genome-wide significant and genome-wide suggestive thresholds of 1.58 × 10^-7^ and 1.58 × 10^-6^, respectively. We performed the quantitative transmission disequilibrium test (QTDT) to test for population stratification ([@B32]). The power calculations were implemented in SOLAR 4.3.

RESULTS
=======

STUDY PARTICIPANTS
------------------

The descriptive characteristics of the GKDZI participants for the variables included in the GWAS are presented in **Table [1](#T1){ref-type="table"}**. The mean age was 37.1 ± 13.6 years and 52% were males. Nearly 19% of the participants were diabetic, 34% were hypertensive, 30% had hyperuricemia, and 24% had CKD at the time of the GKDZI clinic exam. The GWAS included 998 individuals with available DNA samples. Genotype distributions of all significantly associated SNPs conformed to the Hardy--Weinberg equilibrium. Population stratification was not significant as per the QTDT and therefore did not confound our associations.

###### 

Characteristics of traits related to kidney disease, diabetes, and CVD in GKDZI participants.

  Phenotypes        Trait                       *N*        \% or mean (CI)\*      Range
  ----------------- --------------------------- ---------- ---------------------- --------------
  Age               Age (years)                 1000\*\*   37.1 (36.3, 38.0)      18.0--93.1
  Sex               Men (%)                     1000       51.8%                  
  Obesity           BMI (kg/m^2^)               1000       29.6 (29.1, 30.0)      16.8--64.7
  Diabetes          HbA~1c~                     1000       5.8 (5.7, 5.9)         3.8--14.0
                    Diabetes (%)                999        18.5%                  
  Serum Lipids      Total cholesterol (mg/dL)   992        181.3 (179.2, 183.9)   71.0--400
                    HDL-C (mg/dL)               947        50.2 (49.1, 51.2)      17.0--131.0
                    LDL-C (mg/dL)               814        98.8 (96.7, 100.9)     17.0--323.0
                    Triglycerides (mg/dL)       992        169.0 (161.1, 176.8)   11.0--2000.0
  Blood Pressure    SBP (mm Hg)                 1000       122.4 (121.4, 123.4)   81.3--198.7
                    DBP (mm Hg)                 1000       77.6 (76.9, 78.3)      47.3--132.0
                    Hypertensive (%)            1000       33.5%                  
  Kidney Function   Kidney disease (%)          1000       23.5%                  
                    Dialysis (%)                1000       1.2%                   
                    Kidney transplant (%)       1000       0.1%                   
                    Serum albumin               998        4.29 (4.26, 4.32)      2.0--5.5
                    Urine albumin               985        12.7 (9.3, 16.1)       0.08--613.0
                    Serum cystatin C            915        0.86 (0.82, 0.90)      0.44--7.89
                    eGFR~MDRD-AI~               998        115.4 (113.5, 117.2)   4.3--249.3
                    Serum creatinine (mg/dL)    999        0.90 (0.85, 0.95)      0.3--11.2
                    Urine creatinine            985        130.1 (125.0, 135.2)   3.0--460.5
                    UACR                        985        112.7 (80.2, 145.2)    1.0--9378.5

\*Confidence interval.

\*\*Total number of participants in GKDZI study was 1000 of which two were not included in the genome-wide association studies (GWAS).

BMI, body mass index; HbA

1c

, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR

MDRD-AI

, glomerular filtration rate estimated according to the Modification of Diet and Renal Disease modified for American Indians; UACR, urine albumin to creatinine ratio Diabetes, any one of the following: (1) history of diabetes; (2) random plasma glucose ≥200 mg/dL; (3) HbA1c \>7.0%; (4) taking diabetes medication(s).

Hypertensive = (1) history of hypertension; (2) SBP \>140 mm Hg, and/or DBP \>90 mm Hg; (3) currently taking antihypertensive medications.

Kidney disease = (1) UACR \>0.03 in two of three spot urine samples; (2) eGFR

MDRD-AI

\<70; (3) renal replacement therapy.

GENOME-WIDE ASSOCIATION ANALYSIS
--------------------------------

### Kidney traits

A genome-wide significant association was identified for serum creatinine (**Table [2](#T2){ref-type="table"}**). An intronic variant (minor allele G) in the protein tyrosine phosphatase-like A domain containing 2 (*PTPLAD2*) gene on Chromosome 9 was significantly associated (*p* = 1.2 × 10^-7^) with increased serum creatinine concentrations, with an effect size (residual phenotypic variance that is contributed by the minor allele of the SNP) of 3.0%. Evidence of suggestive association was found for serum creatinine with phospholipase A2 group 4a (*PLA2G4A*), ATPase, Class V, type 10B (*ATP10B*), and disks, large homolog 2 (Drosophila; *DLG2*; **Table [2](#T2){ref-type="table"}**). However, we did not find any significant or suggestive associations for eGFR or the urine to albumin creatinine ratio (UACR). In addition, we found significant associations of SUA with several SNPs in solute carrier family 2, member 9 (*SLC2A9*) gene (rs6449213, rs938555, rs16890979, rs12499857, rs734553, rs6832439, rs13125646, rs13131257, rs13145758, and rs9998811; **Figure [2](#F2){ref-type="fig"}**). Minor alleles of most of these SNPs (shown in detail in **Table [3](#T3){ref-type="table"}**) were associated with lower SUA levels.

###### 

GWAS results for kidney function results in Zuni Indians.

  Variable              *N*\*   Chromosome   SNP          *p*-value for association   Major/minor allele   Minor allele frequency   Effect size   Gene symbol gb37           Gene name                                                                      Coordinate gb37   Gene location gb37
  --------------------- ------- ------------ ------------ --------------------------- -------------------- ------------------------ ------------- -------------------------- ------------------------------------------------------------------------------ ----------------- --------------------
  Serum albumin         981     16           rs8056272    1.05 × 10^-6^               A/C                  0.33                     0.02          *LOC100288121 LOC401859*   LOC401859: peptidyl-prolyl cis-trans isomerase A-like pseudogene (genecards)   73710475          INTERGENIC
  Serum creatinine^2^   986     1            rs2383574    8.06 × 10^-7^               G/A                  0.40                     0.03          *PLA2G4A*                  Phospholipase A2, group IVA                                                    187081199         INTERGENIC
  Serum creatinine      986     5            rs11135109   1.07 × 10^-6^               C/A                  0.36                     0.02          *ATP10B*                   ATPase, class V, type 10B                                                      160099440         INTRON
  Serum creatinine      986     9            rs2275887    1.22 × 10^-7^               A/G                  0.43                     0.03          *PTPLAD2*                  Protein tyrosine phosphatase-like A domain containing 2                        21017828          gb37
  Serum creatinine      986     11           rs17147179   9.00 × 10^-7^               G/A                  0.06                     0.03          *DLG2*                     Disks, large homolog 2                                                         84029748          INTRON

∗

number of samples included in GWA analysis.

![**Genome-wide association of serum uric acid (SUA) levels.** Manhattan Plot for the results of the genome wide association analysis with SUA levels. The genome-wide distribution of *p*-values for each of the SUA associated single nucleotide polymorphisms (SNPs) is shown. The adjusted genome-wide significant and genome-wide suggestive thresholds were set at 1.58 × 10^-7^ and 1.58 × 10^-6^, respectively. The x axis represents the genomic position of *SLC2A9* SNPs; the y axis shows the -log10 *p*-value. There were significant associations with 10 *SLC2A9* SNPs (rs6449213, rs938555, rs16890979, rs12499857, rs734553, rs6832439, rs13125646, rs13131257, rs13145758, and rs9998811).](fgene-06-00006-g002){#F2}

###### 

Significant associations and genotype-specific means of serum uric acid (SUA) levels\* (mg/dl).

  *SLC2A9* SNP   Minor allele/frequency   *p*-value       Effect size^a^   A/A^c^       A/G^c^       G/G^c^
  -------------- ------------------------ --------------- ---------------- ------------ ------------ ------------
  rs6449213      G/0.32                   4.5 × 10^-8b^   4.1              6.14 (1.6)   5.80 (1.6)   5.21 (1.5)
  rs16890979     G/0.49                   6.4 × 10^-8^    3.7              5.53 (1.6)   5.90 (1.6)   6.22 (1.6)
  rs938555       G/0.49                   6.6 × 10^-8^    3.7              5.53 (1.6)   5.89 (1.6)   6.22 (1.6)
  rs12499857     G/0.37                   8.4 × 10^-8^    4.3              6.15 (1.6)   5.88 (1.6)   5.23 (1.5)
  rs6832439      G/0.49                   8.5 × 10^-8^    3.6              5.53 (1.6)   5.89 (1.6)   6.22 (1.6)
  rs734553       A/0.49                   8.5 × 10^-8^    3.6              6.24 (1.6)   5.88 (1.6)   5.56 (1.6)
  rs13125646     G/0.49                   1.1 × 10^-7^    3.5              5.56 (1.6)   5.88 (1.6)   6.24 (1.6)
  rs13131257     G/0.49                   1.1 × 10^-7^    3.5              5.56 (1.6)   5.88 (1.6)   6.24 (1.6)
  rs13145758     A/0.49                   1.1 × 10^-7^    3.5              6.24 (1.6)   5.88 (1.6)   5.56 (1.6)
  rs9998811      G/0/49                   1.1 × 10^-7^    3.5              5.56 (1.6)   5.88 (1.6)   6.24 (1.6)
  rs7680126      G/0.49                   1.3 × 10^-7^    3.5              6.21 (1.6)   5.88 (1.7)   5.54 (1.6)
  rs881971       A/0.48                   1.4 × 10^-7^    3.6              6.22 (1.6)   5.92 (1.6)   5.53 (1.6)
  rs13111638     A/0.32                   1.5 × 10^-7^    3.8              5.22 (1.5)   5.80 (1.6)   6.13 (1.6)

∗

number of samples included in GWAS analysis = 993.

a

Proportion of residual phenotypic variance accounted by the minor allele of the single nucleotide polymorphism (SNP).

b

Genome-wide significance level was set at

p

\< 1.58 × 10

-7

.

c

Mean (SD).

### Lipid phenotypes

We analyzed the levels of four lipid phenotypes, e.g., triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and total cholesterol in the GWAS. The strongest association was found for triglycerides for SNPs near the zinc finger protein 259 (*ZNF259*), apolipoprotein A-1 (*APOA1*), and BUD13 homolog (*BUD13*) genes on Chromosome 11 (**Table [4](#T4){ref-type="table"}**). Triglycerides were significantly associated (*p* = 1.83 × 10^-11^ to 6.00 × 10^-8^) with four SNPs near genes and one intronic SNP in *BUD13* whose mean effect size ranged from 3.2 to 4.4% (**Table [4](#T4){ref-type="table"}**). All minor alleles of SNPs (effect sizes ranging between 2.3 and 4.8%) except rs180360 (effect size = 4.9%) were associated with increased triglycerides. Two of the SNPs near *BUD13* (rs10466588, rs6589563) were in complete LD. Two associated SNPs near the *APOA1* gene were also in complete LD. The mean effect size for the two SNPs was 3.6%. **Figure [3](#F3){ref-type="fig"}** provides a Manhattan Plot for the results of the genome-wide association analysis with triglyceride levels. The minor allele (C) of an intronic SNP (rs3852861) in the poliovirus receptor-related 2 (*PVRL2*) gene on Chromosome 19 was significantly associated (*p* = 6.44 × 10^-8^) with increased total cholesterol. The mean effect size was 3.4% (**Table [4](#T4){ref-type="table"}**). We also found evidence of suggestive associations for triglycerides, HDL-, LDL-, and total cholesterol on Chromosomes 17, 16, 2, and 2, respectively.

###### 

GWAS results for lipid traits in Zuni Indians.

  Variable name   Chr   *N*\*   SNP          *p*-value for association   Major/minor allele   Minor allele frequency   Effect size   Gene symbol gb37   Gene name                                                      Coordinate gb37   Gene location gb37
  --------------- ----- ------- ------------ --------------------------- -------------------- ------------------------ ------------- ------------------ -------------------------------------------------------------- ----------------- --------------------
  Cholesterol     2     939     rs2666306    4.54 × 10^-7^               T/A                  0.04                     0.03          *MYADML*           Myeloid-associated differentiation marker-like                 34069629          INTERGENIC
  Cholesterol     19    939     rs3852861    6.44 × 10^-8^               A/C                  0.18                     0.03          *PVRL2*            Poliovirus receptor-related 2 (herpesvirus entry mediator B)   45383061          INTRON
  HDL             16    897     rs7499892    1.09 × 10^-6^               G/A                  0.15                     0.03          *CETP*             Cholesteryl ester transfer protein, plasma                     57006590          INTRON
  LDL             2     775     rs12464255   3.93 × 10^-7^               G/A                  0.13                     0.04          *PLEKHM3*          Pleckstrin homology domain containing, family M, member 3      208926542         INTERGENIC
                                                                                                                                     *CRYGD*            Crystallin, gamma D                                                              
  Triglycerides   11    936     rs964184     1.83 × 10^-11^              G/C                  0.39                     0.05          *ZNF259*           Zinc finger protein 25                                         116648917         INTERGENIC
  Triglycerides   11    936     rs180360     9.83 × 10^-11^              A/G                  0.38                     0.05          *BUD13*            BUD13 homolog                                                  116598988         INTERGENIC
  Triglycerides   11    936     rs6589563    1.04 × 10^-8^               G/A                  0.44                     0.04          *BUD13*            BUD13 homolog                                                  116590787         INTERGENIC
  Triglycerides   11    936     rs10466588   1.09 × 10^-8^               A/G                  0.44                     0.04          *BUD13*            BUD13 homolog                                                  116610249         INTERGENIC
  Triglycerides   11    936     rs180326     6.00 × 10^-8^               A/C                  0.44                     0.03          *BUD13*            BUD13 homolog                                                  116624703         INTRON
  Triglycerides   11    936     rs5072       1.29 × 10^-7^               G/A                  0.31                     0.04          *APOA1*            Apolipoprotein A-I                                             116707583         INTERGENIC
  Triglycerides   11    936     rs2070665    1.29 × 10^-7^               G/A                  0.31                     0.04          *APOA1*            Apolipoprotein A-I                                             116707684         INTERGENIC
  Triglycerides   11    936     rs541407     3.75 × 10^-7^               A/G                  0.38                     0.03          *BUD13*            BUD13 homolog                                                  116313753         INTERGENIC
  Triglycerides   11    936     rs11216129   4.16 × 10^-7^               C/A                  0.24                     0.03          *BUD13*            BUD13 homolog                                                  116620256         INTRON
  Triglycerides   11    936     rs1942478    9.15 × 10^-7^               A/C                  0.23                     0.03          *ZNF259*           Zinc finger protein 25                                         116651463         INTRON
  Triglycerides   11    936     rs12272004   1.30 × 10^-6^               C/A                  0.27                     0.02          *BUD13*            BUD13 homolog                                                  116603724         INTERGENIC
  Triglycerides   17    936     rs2074258    1.14 × 10^-6^               G/A                  0.22                     0.03          *PIK3R6*           PIK3R6 phosphoinositide-3-kinase, regulatory subunit 6         8726160           INTRON

\*Number of samples included in GWA analysis.

![**Genome-wide association analysis of serum triglycerides.** Manhattan Plot for the results of the genome wide association analysis with serum triglyceride levels. The genome-wide distribution of *p*-values for each of the serum triglyceride associated SNPs is shown. The adjusted genome-wide significant and genome-wide suggestive thresholds were set at 1.58 × 10^-7^ and 1.58 × 10^-6^, respectively. The x axis represents the genomic position of the triglyceride associated SNPs; the y axis shows the -log10 *p*-value. The strongest association was for SNPs near the zinc finger protein 259 (*ZNF259*), apolipoprotein A-1 (*APOA1*), and BUD 13 homolog (*BUD13*) genes on Chromosome 11.](fgene-06-00006-g003){#F3}

### Blood pressure

Although GWA analysis of systolic (SBP) and diastolic blood pressure (DBP) yielded no significant associations, several exhibited evidence of suggestive associations (Data not shown). There were associations with two SNPs near the olfactomedin-like 2B (*OLFML2B*) gene on Chromosome 1 that approached significance (*p* = 9.68 × 10^-7^). The average effect size was 3.6% and was associated with increases in SBP. There was one intronic SNP in nuclear factor I/A (*NFIA*) on Chromosome 1 that showed evidence of suggestive association (*p* = 1.23 × 10^-6^) with decreased DBP.

DISCUSSION
==========

The most significant findings of the first GWAS in Zuni Indians were the strong associations of *PTPLAD2, SLC2A9*, *PVRL2,* and *BUD13* with serum levels of creatinine, uric acid, total cholesterol and triglycerides, respectively. Although, GWA analysis of BMI, SBP, DBP, and HbA1c provided no significant associations, some traits approached significance and several exhibited evidence of suggestive association.

We identified a novel significant association of an intronic variant in the *PTPLAD2* gene on Chromosome 9 with an increased serum creatinine concentration. This gene is part of very long chain fatty acid dehydratase HACD family and has a key role in the dehydration step of the very long chain fatty acid metabolism ([@B34]). Also implicated in tumor suppression ([@B81]), this gene has not been previously reported to be associated with serum creatinine. We also found association, albeit suggestive, between serum creatinine and *PLA2G4A, ATP10B,* and *DLG2* SNPs. Their role in kidney function is not clear, except that in the kidney, cytosolic phospholipase A2 seems to play a role in GFR, vascular tone and water transport ([@B15]).

The strong association between SUA levels and *SLC2A9* SNPs is a replication and confirmation of these associations in several populations. Most of these studies were conducted in European populations ([@B14]; [@B43]; [@B69]) as well as in Asian ([@B64]; [@B28]), African American ([@B13]; [@B53]; [@B68]) and Mexican American populations ([@B71]). The effect sizes or the proportion of residual variance in a phenotype that is explained by the minor allele of the SNP ranged between 3.5 and 4.3% in this study which is similar to what has been reported by these studies. Similar results were found in a candidate gene study in American Indians where only seven *SLC2A9* SNPs were genotyped ([@B70]). In addition, [@B10] not only confirmed this association in six different cohorts of European ancestry but showed that SLC2A9 can exchange glucose for urate in the process of secretion of urate into the urine in functional studies.

Hyperuricemia is associated with hypertension ([@B35]), CKD ([@B38]), insulin resistance ([@B11]), and cardiovascular disease ([@B52]), although causality has not been established. SLC2A9 was originally identified as glucose transporter 9 (GLUT9). However, it facilitates electrogenic transport of both hexoses and uric acid in the proximal tubule ([@B77]). There are two forms, SLC2A9a and SLC2A9b, which are expressed in the basolateral and apical membranes of the proximal tubule, respectively. Their amino acid sequences are identical, except that SLC2A9b has a shorter and modified N-terminus. Both forms are active in urate transport in the proximal tubule ([@B39]). Kidney function and SUA are interrelated ([@B37]). The anti-hypertensive drug losartan lowers SUA ([@B9]; [@B78]; [@B29]) and confers long-term protection of kidney function ([@B8]). A recent GWAS conducted in Mexican Americans, reported a nominal association between UACR and *SLC2A9* SNPs ([@B71]). We found nominal associations between *SLC2A9* SNPs and kidney function phenotypes (Data not shown). Our results related to kidney function phenotypes replicate results of studies conducted in Mexican Americans and other American Indian tribes ([@B71], [@B70]). However, our study is different from others as the participating individuals in our study were ascertained for CKD.

Total serum cholesterol was significantly associated with an intronic SNP (rs3852861) in the *PVRL2* gene on Chromosome 19. *PVRL2* is located 17 kb downstream from the apolipoprotein E (*APOE*) gene and has also been associated with severity of multiple sclerosis ([@B19]; [@B55]), late-onset Alzheimer's disease ([@B12]), and peripheral T-cell lymphomas ([@B44]). A study of Caucasian patients with coronary artery disease found a relationship between homozygosity of the A allele in a polymorphism of the *PVRL2/PRR2* gene and premature cardiovascular disease ([@B25]). The authors suggested that this finding could be related to viral association or linkage disequilibrium between *PRR2* and nearby (17 kb centromeric) apolipoprotein E (*APOE*; [@B75]). This gene was also associated with LDL cholesterol in a Caucasian population although the chromosomal region is not the same ([@B65]). We also found evidence of suggestive association of cholesterol esterase transfer protein (*CETP*) with HDL cholesterol which is a replication of several studies ([@B22]; [@B59]; [@B72]).

The association of triglycerides with four SNPs near and one SNP in the *BUD13/ZNF259* region replicates results observed in a Mexican cohort ([@B74]), a meta-analysis of individuals of European descent ([@B56]), a Finnish cohort ([@B40]) and Asian Indians ([@B7]). The minor allele frequency for rs964184 is higher among Zuni Indians (39%) than among Mexicans (27%), Asian Indians (15%) or Whites (12%). The *ZNF259/BUD13* associations with triglyceride levels have been reported in GWAS in the Framingham Study ([@B63]), which also showed an association with lipoprotein-associated phospholipase A2 (Lp-PLA2), a risk factor and possible therapeutic locus for CVD. Similarly, *ZNF259* was significantly associated with Lp-PLA2 activity in a meta-analysis of five population-based studies ([@B27]). *ZNF259* codes for ZPR1, a zinc (as well as some other metals) binding protein, which may play a role in signal transfer from cell cytoplasm to the nucleus and cell proliferation ([@B26]). This region of the *ZNF259/BUD13, APOA1/C3/A4/A5* genes has also been associated with coronary artery disease ([@B73]).

In addition, we also found some novel, albeit suggestive, associations of various SNPs with cardiometabolic phenotypes such as SNPs near *OLFML2B* and *NOS1AP* with blood pressure phenotypes. Although these SNPs have not been associated with blood pressure before, they have been associated with the Short QT-Syndrome among individuals from the UK and North America ([@B18]; [@B50]). Similarly, variants in the *NFIA* gene, which encodes the nuclear factor 1 family of transcription factors have been associated with QRS duration in individuals of European descent ([@B61]).

STRENGTHS AND LIMITATIONS
-------------------------

The strengths of our study include a dense GWAS using an Illumina chip that was state of the art at the time the study was conducted. Conducting the study in extended families from a relatively endogamous population increased our statistical power and minimized potential population stratification. Furthermore, we utilized state of the art programs for conducting genetic analyses (SOLAR, MERLIN). All study staff members working in Zuni were Zuni, which enhanced community acceptance of performing genetic studies in the Pueblo. Our study also had some significant limitations. We did not perform direct measurements of GFR. The serum creatinine assay was performed in a clinical laboratory and not standardized. The GFR estimating equation has not been validated in Zuni Indians. Kidney biopsies were not performed and may have led to misclassification. We did not account for all possible genetic X environmental interactions. In addition, we did not have positive controls. However, several of our significant loci have been previously identified in individuals without kidney disease.

CONCLUSION
==========

The results of the GKDZI study support our hypothesis that genetic factors significantly influence susceptibility to CKD and related cardiometabolic phenotypes among Zuni Indians.
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